Skip to content
Catalyst

knowcompoundsfucoxanthin

Specimen compound organic compound

Fucoxanthin

An epoxycarotenol that is found in brown seaweed and which exhibits anti-cancer, anti-diabetic, anti-oxidative and neuroprotective properties.”

fig. 1Fucoxanthin · findings by direction and evidence strength
Formula
C42H58O6
Molar mass
658.92 g/mol
InChIKey
SJWWTRQNNRNTPU-XJUZQKKNSA-N

↓ lowered 1 finding in 1 endpoint · – no difference found 1 in 1

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
0
Limited
0
Very limited
3
Insufficient
3

How to read these marks

Fig. 2 Fucoxanthin CHEBI:5186 5 endpoints 6 findings
×1.60
Labels
CompoundInspector

Fucoxanthin

Most findings

  • Alanine aminotransferase×2
  • EPHB2×1
  • KEAP1×1
  • SIRT1×1
  • TLR4×1

36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. Binds KEAP1
  2. Inhibits EPHB2
  3. Inhibits TLR4
  4. Alanine aminotransferasecontested
  5. Activates SIRT1
fig. 3 · 5 endpoints · 6 findingscontested · an endpoint whose findings disagree

02 · contested · 1 endpoint

Where the findings disagree

  1. 012 findings

    Alanine aminotransferase

    ↓ lowered
    1
    – no difference found
    1

03 · findings

What fucoxanthin moved, and by how much

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Direction
Strength, at least

6 shown

  1. TLR4Moved: inhibitsEvidence: Very limitedPaper: PMID 354478992022
    Who
    Human Chang liver cell line, FFA-induced NAFLD cell model, fucoxanthin group
    Dose studied
    not reported

    The expression of TLR4 and its downstream proteins myeloid differentiation factor 88 (MyD88), p-IκBα, and p-NF-κBp65 was significantly upregulated in the FFA group, and was significantly inhibited by treatment with fucoxanthin.”

    Quoted verbatim from Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.in vitro · not in humansPermalink
  2. EPHB2Moved: inhibitsEvidence: Very limitedPaper: PMID 336737042021
    Who
    RAW264.7 murine macrophage cells stimulated with sRANKL or TNF-alpha/IL-6
    Dose studied
    0, 1, 2.5 and 5 uM FX

    The treatment of RAW264.7 cells with FX significantly reduced the phosphorylation of ERK and p38 in a concentration-dependent manner.”

    Quoted verbatim from Fucoxanthin Suppresses Osteoclastogenesis via Modulation of MAP Kinase and Nrf2 Signaling.in vitro · not in humans · 4 daysPermalink
  3. KEAP1Moved: bindsEvidence: Very limitedPaper: PMID 337773212021
    Who
    purified human Keap1 protein, biolayer interferometry
    Dose studied
    not reported

    shows that FUC bound to Keap1 protein in a dose-dependent manner, with constant of KD = 5.16 E − 5, constant of Kon = 6.73 E + 2, and constant of Koff = 3.47 E − 2.”

    Quoted verbatim from Fucoxanthin Prevents 6-OHDA-Induced Neurotoxicity by Targeting Keap1.in vitro · not in humansPermalink
  4. SIRT1Moved: activatesEvidence: InsufficientPaper: PMID 338650172021
    Who
    C2C12 myotubes with dexamethasone-induced atrophy
    Dose studied
    fucoxanthin 10 μM

    Through activating SIRT1, fucoxanthin inhibits forkhead box O (FoxO) transcriptional activity to reduce protein degradation, induces autophagy to enhance degraded protein clearance, promotes mitochondrial function and diminishes apoptosis.”

    Quoted verbatim from Fucoxanthin rescues dexamethasone induced C2C12 myotubes atrophy.in vitro · not in humansPermalink
  5. Alanine aminotransferasecontestedMoved: lowersEvidence: InsufficientPaper: PMID 311379222019
    Who
    female C57BL/6J mice fed a high-fat diet for 6 weeks; FX arm compared with the high-fat-diet control arm
    Dose studied
    FX 0.1 mg/kg/day

    FX and PE-M + CLA treatment significantly decreased ALT levels, whereas PE treatment slightly decreased ALT levels, compared with those in the HFD group.”

    Quoted verbatim from Anti-Obesity Effect of Standardized Extract of Microalga Phaeodactylum tricornutum Containing Fucoxanthin.animal · not in humans · 6 weeksPermalink
  6. Alanine aminotransferasecontestedMoved: no difference foundEvidence: InsufficientPaper: PMID 356840792022
    Who
    C57BL/6J mice, pooled across HFC (high-fat/high-sucrose/high-cholesterol) and HFS (high-fat/high-sucrose) diet-induced obesity models, FCX-supplemented diet vs same diet without FCX
    Dose studied
    0.015% or 0.03% w/w FCX in HFC diet, 12 weeks; 0.01% w/w FCX in HFS diet, 8 weeks

    No significant differences were present in liver triglyceride and total cholesterol, hepatic fat accumulation, and serum alanine aminotransferase levels between control and FCX-fed mice regardless of whether they were on an HFC or HFS diet.”

    Quoted verbatim from Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity.animal · not in humansPermalink

No dose is advised.

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

04 · identity

Structure

fig. 4Fucoxanthin · 2D structure · ChEBI’s SMILES
Charge
0
3D model
None at PubChem
SMILES
[H]C(=C=C1C(C)(C)C[C@H](OC(C)=O)C[C@@]1(C)O)/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)C(=O)C[C@@]12O[C@]1(C)C[C@@H](O)CC2(C)C

05 · reach

What it touches on the way

3 entities · assembled from reference reactions

  1. SIRT1Protein62 paths · 62 endpointsinferred
  2. TLR4Protein33 paths · 33 endpointsinferred
  3. EPHB2Protein24 paths · 24 endpointsinferred

06 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Trials · ClinicalTrials.gov
2registered without posted results · 2 past the reporting window
2Registered trials without posted results

Registered, and not reported

Source
ClinicalTrials.gov
Intervention
fucoxanthin
Status
Completed, terminated or suspended
Results posted
No

Trials without posted results

2 trials

2 registered trials without posted results · Overdue (FDAAA 801): 2

2 past the window0 within it, or no actual date

  • NCT04761406completed2023-05-01industrypast the reporting window
  • NCT04851899completed2022-06-01industrypast the reporting window

07 · on the label · 58 products

Labelled products

Source: NIH DSLD · Ingredient: fucoxanthin · 58 products · Declared amount per serving: 0.5–500 mg

30 labels state an amount28 do not

  • 1st PhormL-Carnitine Strawberry Mango2.5 mgper 4 gDSLD:262223
  • Alpha LionApex Burn Cherry Blaze10%50 mgper 3.25 gDSLD:315549
  • AlpileanAlpileanseaweed · 10%amount not statedper 1 capsuleDSLD:299241
  • AnoviteLimuzu 6 Natural Fruit Flavoramount not statedper 7.2 gDSLD:319485
  • ATS Labs01-02 Enhanced Fat Melting Matrixamount not statedper 1 capsuleDSLD:218923
  • Best NaturalsFucoxanthin with Fucoplast5%100 mg · amount not statedper 3 capsulesDSLD:269637
  • BiOptimizersBlood Sugar Breakthrough10%amount not statedper 2 capsulesDSLD:320981
  • BioSource LabsComplex Diet Dropsamount not statedper 0.5 mLDSLD:313582
  • BRI NutritionFucoxanthinFucoxanthin, from Brown Seaweed5 mgper 1 capsuleDSLD:219005
  • CellucorStimulant Free Fat Burner75 mgper 1 capsuleDSLD:3679
  • CellucorStimulant Free Fat Burner75 mgper 1 capsuleDSLD:3686
  • CellucorT7 Extreme75 mgper 1 capsuleDSLD:3684
Show the remaining 46Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

08 · the record

Sources

578

papers screened for fucoxanthin

admitted
6
read and discarded
382
not read yet
190

The screening record, every paper and why

Sources cited

6 papers · 6 findings

Show every paper citedHide the papers cited

Other names · 3

(3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-β,β-caroten-8-one · (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-β,β-carotene

systematic · (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-β,β-caroten-3'-yl acetate